Published in Obesity and Diabetes Week, February 15th, 2010
"Extensive investigations of ADME and in vivo pharmacological properties led to selection of the amide series and specifically the 4-(4-fluorophenyl)piperidin-4-ol derivative D4," wrote J.M. Receveur and colleagues, 7TM Pharma.
The researchers concluded: "A clear improvement in the peripheral pro. le over...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week